Effects and mechanisms of Supplemented Gegen Qinlian Decoction Formula against podocyte pyroptosis and insulin resistance in model rats with diabetic kidney disease

This study explored the in vivo effects and mechanisms of the modern classical prescription Supplemented Gegen Qinlian Decoction Formula(SGDF) against diabetic kidney disease(DKD). Sixty rats were randomly divided into the normal group, model group, SGDF group, and rosiglitazone(ROS) group. The modified DKD rat model was established by employing the following three methods: exposure to high-fat diet, unilateral nephrectomy, and intraperitoneal injection of streptozotocin(STZ). After modeling, rats in the four groups were treated with double distilled water, SGDF suspension, and ROS suspension, respectively, by gavage every day. At the end of the 6 th week of drug administration, all the rats were sacrificed for collecting urine, blood, and kidney tissue, followed by the examination of rat general conditions, urine and blood biochemical indicators, glomerulosclerosis-related indicators, podocyte pyroptosis markers, insulin resistance(IR)-related indicators, and key molecules in the insulin receptor substrate(IRS) 1/phosphatidylinositol-3-kinase(PI3 K)/serine threonine kinase(Akt) signaling pathway. The results showed that SGDF and ROS improved the general conditions, some renal function indicators and glomerulosclerosis of DKD model rats without affecting the blood glucose(BG). Besides, they ameliorated the expression characteristics and levels of podocyte pyroptosis markers, alleviated IR, and up-regulated the protein expression levels of the key molecules in IRS1/PI3 K/Akt pathway to varying degrees. In conclusion, similar to ROS, SGDF relieves DKD by targeting multiple targets in vivo. Specifically, it exerts the therapeutic effects by alleviating podocyte pyroptosis and IR. This study has preliminarily provided the pharmacological evidence for the research and development of new drugs for the treatment of DKD based on SGDF.

Medienart:

E-Artikel

Erscheinungsjahr:

2021

Erschienen:

2021

Enthalten in:

Zur Gesamtaufnahme - volume:46

Enthalten in:

Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica - 46(2021), 17 vom: 18. Sept., Seite 4471-4479

Sprache:

Chinesisch

Beteiligte Personen:

Wang, Mei-Zi [VerfasserIn]
Yue, Li-Jun [VerfasserIn]
Wan, Yi-Gang [VerfasserIn]
Huang, Huang [VerfasserIn]
Wu, Wei [VerfasserIn]
Tu, Yue [VerfasserIn]
Liu, Bu-Hui [VerfasserIn]
Fang, Qi-Jun [VerfasserIn]
Yuan, Can-Can [VerfasserIn]
Wang, Jie [VerfasserIn]
Li, Huan [VerfasserIn]
Wan, Zi-Yue [VerfasserIn]

Links:

Volltext

Themen:

Diabetic kidney disease
Drugs, Chinese Herbal
Gegenqinlian
Insulin resistance
Insulin signaling pathway
Journal Article
Podocyte pyroptosis
Supplemented Gegen Qinlian Decoction Formula

Anmerkungen:

Date Completed 29.09.2021

Date Revised 29.09.2021

published: Print

Citation Status MEDLINE

doi:

10.19540/j.cnki.cjcmm.20210524.406

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM331226413